Search

Displaying results 5371 - 5380 of 7604 in total
  1. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    Although the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.

  2. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase ...

    Synonyms: N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester
  3. Drug

    R-348

    go.drugbank.com/drugs/DB06321
    Investigational

    Synonyms: 5-Fluoro-N-(4-methyl-3-propionylaminosulfonylphenyl)-N'-(4-(prop-2-ynyloxy)phenyl)-2,4-pyrimidinediamine
  4. Drug

    Flumequine

    go.drugbank.com/drugs/DB08972
    ApprovedWithdrawn

    Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.

  5. Drug

    Dimazole

    go.drugbank.com/drugs/DB13858
    ApprovedWithdrawn

    It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.

  6. Drug

    Ustilago nuda hordei

    go.drugbank.com/drugs/DB10835
    Approved

    Ustilago nuda hordei is a fungus which can provoke allergic reactions. Ustilago nuda hordei extract is used in allergenic testing.

    Categories: Non-Standardized Fungal Allergenic Extract
  7. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

  8. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

  9. Drug

    Luvometinib

    go.drugbank.com/drugs/DB21696
    Investigational

    Luvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).

  10. Drug

    Eleuthero

    go.drugbank.com/drugs/DB14303
    ApprovedInvestigational

    It is not an approved drug.